Pharmatech Powerhouse AQEMIA Secures $30M in Series A Funding to Accelerate Drug Discovery Innovations

We are thrilled to announce that AQEMIA has successfully raised $30 million in our latest funding round, a significant milestone that will propel our mission of revolutionizing drug discovery for critical diseases, including those in the field of immuno-oncology. As a next-generation pharmatech company, we are harnessing the power of quantum-inspired physics algorithms to fuel our groundbreaking generative AI technologies, enabling us to design novel drug candidates with unprecedented speed and efficiency—without the need for traditional experimental data. This innovative approach has allowed us to achieve remarkable successes in our internal pipeline, along with several fruitful collaborations with top pharmaceutical companies. With this fresh influx of capital, we aim to further enhance our drug discovery capabilities, particularly as our most advanced programs move into in vivo optimization stages. This funding will also support our continued growth as we actively expand our team, inviting talented individuals to join our mission. If you’re passionate about shaping the future of medicine and want to be part of a dynamic environment at the forefront of technology and healthcare, check out our career opportunities at [AQEMIA Careers](https://jobs.lever.co/aqemia.com). You can also peek behind the scenes of our innovative culture and see what makes AQEMIA so unique by visiting our [Welcome to the Jungle page](https://www.welcometothejungle.com/fr/companies/aqemia). We’re excited about the journey ahead and look forward to making impactful strides in drug discovery together!